However, although specific toxicity toward B-Raf mutant melanoma cells has been observed both in vitro and in xenograft melanoma tumors in mice [481,482,483,484], development of LeTx variants with lower in vivo toxicity and high tumor specificity would be required for use in human cancer patients [485]. Here, BRAF is linked to melanoma.